Medtronic plc. (MDT) Stock

Understand Medtronic plc.: how it makes money

Medtronic makes implantable and surgical medical devices (pacemakers, defibrillators, ablation systems, neurostimulators, surgical tools) sold to hospitals and physicians worldwide. Cardiovascular is the largest portfolio at 38% of revenue, with the business split roughly 50/50 between the US and international markets.

Once a pacemaker, defibrillator, or neurostimulator is implanted, the patient is locked into a recurring stream of follow-up visits, consumables, and eventual device upgrades that a competitor cannot reach without a risky re-operation; that installed base is what支撑s the 64% gross margin.

Business quality (Mixed): Solid but not elite: a 64% gross margin reflects high R&D content and regulatory moats, yet a 16% operating margin trails higher-margin peers like Intuitive. The diversified multi-portfolio model reduces single-product risk but caps margin expansion, and the 24x multiple prices in that 'good but not great' quality tier.

Valuation: At 24× earnings, MDT trades 25% below the Medical Equipment average (33×).

Bull case

• Ablation engine outgrowing market: Cardiac Ablation Solutions is expected to grow more than twice the mid-to-high-teens market rate in FY27, meaning even a slower broader market still delivers double-digit CAS growth for Medtronic. That accelerates the largest segment's contribution beyond the already-strong 10.6% organic pace.
• Trading at a clear discount: The stock screens at P/E 24.4x versus the Medical Equipment industry average of 33x, a 25% discount. If tariff headwinds prove transitory and CAS/Simplicity inflections hold, the valuation gap offers a margin of safety relative to similarly growing medtech peers.
• M&A extends the runway: Recent acquisitions are expected to add approximately $150 million of FY27 inorganic revenue, giving management a bolt-on growth lever on top of the organic engine without relying on any single new product reaching scale.

Bear case

• Tariffs eroding gross profit: FY27 guidance bakes in approximately $250 million of tariff impact, up $65 million year over year. This is a direct hit to the 64% gross margin and, unlike a one-time charge, scales with revenue growth if trade policy persists.
• TAVR momentum stalling: TAVR growth slowed after low-risk data, particularly in the United States, which removes one of Medtronic's fastest-growing structural-heart drivers just as the competitive field (Abbott, Edwards) intensifies in that category.
• Guidance embeds a margin drag: FY27 EPS already includes an approximately 200-basis-point below-operating-profit headwind, and medical-surgical growth is expected to normalize after a strong Q4. Together these compress near-term EPS even if top-line growth holds around the low-double-digit organic pace.

Medtronic plc. earnings call transcripts

• MDT Q1 FY27 earnings call transcript (reported 2026-09-01) · analysis
• MDT Q4 FY26 earnings call transcript (reported 2026-06-03) · analysis
• MDT Q1 FY26 earnings call transcript (reported 2025-08-19) · analysis

All MDT earnings calls

Related Companies (Medical Equipment; 8 comparable device makers)

• Becton, Dickinson and Company (BDX)
• Boston Scientific Corporation (BSX)
• Danaher Corporation (DHR)
• Thermo Fisher Scientific Inc (TMO)
• Intuitive Surgical, Inc. (ISRG)
• Edwards Lifesciences Corporation (EW)
• DexCom, Inc. (DXCM)
• The Cooper Companies, Inc. (COO)